NZ714128A - 4-1bb binding molecules - Google Patents

4-1bb binding molecules

Info

Publication number
NZ714128A
NZ714128A NZ714128A NZ71412811A NZ714128A NZ 714128 A NZ714128 A NZ 714128A NZ 714128 A NZ714128 A NZ 714128A NZ 71412811 A NZ71412811 A NZ 71412811A NZ 714128 A NZ714128 A NZ 714128A
Authority
NZ
New Zealand
Prior art keywords
binding molecules
disclosed
extracellular domain
cdr sequences
binds human
Prior art date
Application number
NZ714128A
Other languages
English (en)
Inventor
Bianca Ahrens
Sangita M Baxi
Simon Paul Bergqvist
Regis Doyonnas
Robert Lee Dufield
Mark William Elliott
Timothy Scott Fisher
Richard Michael Jerome
Heather Laurence Jones
Cris Kamperschroer
Kathrin Ladetzki-Baehs
Victoria Alexandria Love
Theodore Lawrence Oliphant
Adekunle Olatunbosun Onadipe
Wenning Qin
Vinay Radhakrishnan
Allison Karlyn Rohner
Leslie Lynne Sharp
Michael Tesar
Kristin Elizabeth Thomas
Libbey Anne Yates
Daisy Marie Ziegemeier
Moritz Zulley
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to NZ729044A priority Critical patent/NZ729044A/en
Publication of NZ714128A publication Critical patent/NZ714128A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ714128A 2010-09-09 2011-08-26 4-1bb binding molecules NZ714128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38121010P 2010-09-09 2010-09-09
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Publications (1)

Publication Number Publication Date
NZ714128A true NZ714128A (en) 2017-10-27

Family

ID=44759732

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ714128A NZ714128A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Country Status (27)

Country Link
US (5) US8337850B2 (enExample)
EP (2) EP2614082B1 (enExample)
JP (4) JP6105470B2 (enExample)
KR (2) KR101527300B1 (enExample)
CN (2) CN105481983B (enExample)
AR (2) AR082916A1 (enExample)
AU (3) AU2011300445B2 (enExample)
BR (1) BR112013005699B1 (enExample)
CA (1) CA2810359C (enExample)
CO (1) CO6690759A2 (enExample)
DK (1) DK2614082T3 (enExample)
ES (1) ES2699648T3 (enExample)
HU (1) HUE041958T2 (enExample)
IL (3) IL225001A (enExample)
MX (2) MX374682B (enExample)
MY (2) MY177065A (enExample)
NZ (4) NZ714128A (enExample)
PE (1) PE20131465A1 (enExample)
PH (2) PH12020550156A1 (enExample)
PL (1) PL2614082T3 (enExample)
PT (1) PT2614082T (enExample)
RU (2) RU2710717C2 (enExample)
SG (3) SG10201912092VA (enExample)
SI (1) SI2614082T1 (enExample)
TW (4) TWI641621B (enExample)
WO (1) WO2012032433A1 (enExample)
ZA (1) ZA201502914B (enExample)

Families Citing this family (428)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2699598B1 (en) * 2011-04-19 2019-03-06 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
EP2951199A4 (en) * 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
EP3066127A1 (en) * 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
HUE054183T2 (hu) 2013-12-24 2021-08-30 Bristol Myers Squibb Co Triciklusos vegyület rákellenes szerekként
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
MX2016015181A (es) * 2014-05-21 2017-05-25 Pfizer Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
AU2016219772A1 (en) 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
PE20171789A1 (es) 2015-03-02 2017-12-28 Bristol Myers Squibb Co Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
JP2018519245A (ja) 2015-04-03 2018-07-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
EP3294736B1 (en) 2015-05-11 2020-07-22 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
AU2016265447B2 (en) * 2015-05-21 2022-06-16 Alligator Bioscience Ab Novel polypeptides
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
KR20180034548A (ko) 2015-07-28 2018-04-04 브리스톨-마이어스 스큅 컴퍼니 Tgf 베타 수용체 길항제
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
EP3341372A1 (en) 2015-08-25 2018-07-04 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN113214398B (zh) 2015-09-22 2022-04-08 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CA3005855A1 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
RU2745707C2 (ru) 2015-11-23 2021-03-30 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｘｃｒ４受容体アンタゴニスト
MX2018008308A (es) 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
BR112018014016A2 (pt) 2016-01-25 2019-02-05 Pfizer combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
WO2017192813A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452029A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
JP2019516681A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
KR20190003685A (ko) 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
MX2018015684A (es) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
UA128304C2 (uk) 2016-07-14 2024-06-05 Ґенмаб А/С Мультиспецифічне антитіло до cd40 і cd137
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
MA45919A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
JP7009448B2 (ja) 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
CN106244611B (zh) * 2016-08-23 2019-05-17 浙江普康生物技术股份有限公司 一种细胞免疫佐剂tsa-41的制备方法及应用
CN109843322A (zh) 2016-08-26 2019-06-04 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3544628A4 (en) * 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
KR102903340B1 (ko) 2017-01-06 2025-12-26 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
JP6609724B1 (ja) 2017-01-06 2019-11-20 ユーティレックス カンパニー リミテッド 抗ヒト４−１ｂｂ抗体およびその使用
CN110740748A (zh) * 2017-01-17 2020-01-31 芝加哥大学 肿瘤微环境中功能障碍的抗原特异性cd8+t细胞
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
TWI781136B (zh) 2017-01-20 2022-10-21 美商阿克思生物科學有限公司 用於治療癌症相關病症之唑嘧啶
AU2018218345B2 (en) 2017-02-10 2025-04-03 Genmab B.V. Polypeptide variants and uses thereof
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP2020512357A (ja) 2017-03-31 2020-04-23 ファイブ プライム セラピューティクス， インコーポレイテッド 抗ｇｉｔｒ抗体を使用した癌の併用療法
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
FI3612030T3 (fi) 2017-04-21 2026-03-20 Pahr Therapeutics Inc Ahr:n indoliestäjiä ja niiden käyttötapoja
AU2018258661A1 (en) * 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018213377A1 (en) 2017-05-17 2018-11-22 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
MX2019014265A (es) 2017-06-01 2020-08-03 Compugen Ltd Tratamientos conjuntos triples con anticuerpos.
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
AU2018281830B2 (en) 2017-06-09 2023-11-02 Agonox, Inc. Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
WO2019005638A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-4-1BB ANTIBODIES AND METHODS OF PREPARATION AND USE
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
EA202090119A1 (ru) 2017-06-30 2020-04-21 Бристол-Маерс Сквибб Компани Аморфные и кристаллические формы ido-ингибиторов
EP3652209A2 (en) * 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
IL272103B2 (en) 2017-07-20 2024-10-01 Aptevo Res & Development Llc Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
ES2932354T3 (es) 2017-07-28 2023-01-18 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticáncer
JP6743320B1 (ja) * 2017-08-01 2020-08-19 イーライ リリー アンド カンパニー 抗ｃｄ１３７抗体
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As PD-L1 and CD137 binding agents and their use
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
SG11202001310SA (en) 2017-08-17 2020-03-30 Ikena Oncology Inc Ahr inhibitors and uses thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
SG11202002982YA (en) 2017-10-10 2020-04-29 Numab Therapeutics AG Multispecific antibody
US11578133B2 (en) 2017-10-10 2023-02-14 Namab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
EP3697801B1 (en) 2017-10-16 2024-11-20 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
CN111542544A (zh) 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
WO2019091384A1 (en) 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
TWI701259B (zh) 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
CN111601883B (zh) 2017-11-17 2024-06-21 艾欧凡斯生物治疗公司 由细针抽吸物和小活检物扩增til
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN110003332B (zh) * 2018-01-05 2021-05-11 上海原能细胞医学技术有限公司 Cd137抗体及其应用
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
KR102956273B1 (ko) 2018-01-08 2026-04-24 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
KR20200110356A (ko) 2018-01-15 2020-09-23 화이자 인코포레이티드 키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3744734A1 (en) * 2018-01-22 2020-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
JP7377207B2 (ja) 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
EP4616913A3 (en) 2018-01-29 2025-12-10 Merck Patent GmbH Gcn2 inhibitors and uses thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
CN111818923A (zh) 2018-02-16 2020-10-23 艾库斯生物科学有限公司 用唑并嘧啶化合物给药
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
US12054500B2 (en) 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
MX2020009359A (es) 2018-03-08 2021-01-29 Rubius Therapeutics Inc Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas.
US11945834B2 (en) 2018-03-08 2024-04-02 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
MX2020009786A (es) 2018-03-21 2020-10-12 Five Prime Therapeutics Inc Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
KR20240017090A (ko) * 2018-03-23 2024-02-06 일라이 릴리 앤드 캄파니 항-pd-1 항체와의 조합을 위한 항-cd137 항체
KR102432046B1 (ko) * 2018-03-23 2022-08-12 일라이 릴리 앤드 캄파니 항-pd-l1 항체와의 조합을 위한 항-cd137 항체
SMT202400287T1 (it) 2018-03-29 2024-09-16 Iovance Biotherapeutics Inc Procedimenti per la produzione di linfociti infiltranti il tumore e loro usi in immunoterapia
US11993655B2 (en) 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
EP3773720A4 (en) * 2018-04-10 2022-01-05 Wuxi Biologics (Shanghai) Co. Ltd. MONOCLONAL ANTIBODIES AGAINST HUMAN 4-1BB, METHOD OF MANUFACTURING AND USING THEREOF
JP2021521182A (ja) 2018-04-12 2021-08-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
CA3094235A1 (en) 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
AU2019255196A1 (en) 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
EP3784254A1 (en) 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
RS64641B1 (sr) 2018-06-27 2023-10-31 Bristol Myers Squibb Co Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
WO2020014327A2 (en) 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
US11939381B2 (en) 2018-07-19 2024-03-26 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
CA3105891A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020023846A1 (en) 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP3852524B1 (en) 2018-09-20 2023-06-28 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CN113518647A (zh) 2018-10-11 2021-10-19 印希比股份有限公司 5t4单域抗体及其治疗性组合物
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
TW202039829A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 改善之腫瘤反應性ｔ細胞的選擇
CR20210295A (es) 2018-11-05 2021-07-09 Iovance Biotherapeutics Inc Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
WO2020102646A2 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
PE20211778A1 (es) * 2018-11-30 2021-09-08 Abl Bio Inc Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020131547A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
JP7558534B2 (ja) * 2019-01-02 2024-10-01 キューエルエスエフ バイオセラピューティック インコーポレイテッド Ｃｄ１３７アゴニスト性抗体とその使用
JP7539897B2 (ja) * 2019-01-16 2024-08-26 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトｃｄ１３７に結合する抗体の製剤およびその使用
IL284687B2 (en) 2019-02-26 2025-11-01 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
JP2022528887A (ja) 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2020231809A1 (en) 2019-05-10 2020-11-19 Lyvgen Biopharma Co., Ltd. Humanized anti-cd137 antibodies and uses thereof
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
JP2022533833A (ja) 2019-05-24 2022-07-26 ファイザー・インク Ｃｄｋ阻害剤を使用した組合せ療法
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP3980443A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Multispecific proteins
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251971A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
PH12022550605A1 (en) 2019-09-13 2023-09-25 Nimbus Saturn Inc Hpk1 antagonists and uses thereof
MX2022003204A (es) 2019-09-19 2022-04-18 Bristol Myers Squibb Co Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
WO2021059136A1 (en) 2019-09-25 2021-04-01 Pfizer Inc. Polyheterocyclic modulators of sting (stimulator of interferon genes)
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN114269788B (zh) 2019-11-13 2024-08-20 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子及其应用
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
KR20220103753A (ko) 2019-11-19 2022-07-22 브리스톨-마이어스 스큅 컴퍼니 헬리오스 단백질의 억제제로서 유용한 화합물
MX2022006308A (es) 2019-11-26 2022-06-22 Ikena Oncology Inc Derivados de carbazol polimorfos y usos de los mismos.
WO2021108288A1 (en) 2019-11-26 2021-06-03 Bristol-Myers Squibb Company Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
KR20220122639A (ko) 2019-11-27 2022-09-02 미스트 쎄라퓨틱스, 엘엘씨 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
EP4072591A4 (en) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. IRAQ DEGRADER AND USES THEREOF
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
ES2969732T3 (es) 2019-12-18 2024-05-22 Pfizer Régimen de tratamiento del cáncer una vez al día con un inhibidor de PRMT5
US12569485B2 (en) 2019-12-23 2026-03-10 Kymera Therapeutics, Inc. SMARCA inhibitors and uses thereof
ES3013568T3 (en) 2019-12-23 2025-04-14 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
BR112022012220A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
CA3166898A1 (en) 2020-01-06 2021-07-15 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
CA3161733A1 (en) 2020-01-07 2021-05-15 Everett Stone Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
TW202140473A (zh) 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1抑制劑
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
WO2021174208A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
CN115151573A (zh) * 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
KR20220148209A (ko) * 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
KR20220148228A (ko) * 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
IL296451B2 (en) 2020-03-19 2026-05-01 Kymera Therapeutics Inc MDM2 joints and their uses
IL295569B1 (en) 2020-03-19 2026-04-01 Arcus Biosciences Inc Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2ALPHA
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CA3182887A1 (en) 2020-05-13 2021-11-18 Pfizer Inc. Methods, therapies and uses for treating cancer
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022027058A1 (en) 2020-07-30 2022-02-03 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
US20230303695A1 (en) 2020-08-10 2023-09-28 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
CN116194105A (zh) 2020-09-14 2023-05-30 辉瑞大药厂 治疗癌症的方法、疗法及用途
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
CN114195900B (zh) 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN114457026A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
IL303376A (en) 2020-12-02 2023-08-01 Ikena Oncology Inc Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
CA3202330A1 (en) 2020-12-16 2022-06-23 Anthony Casarez Compounds useful as t cell activators
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022147465A1 (en) 2020-12-30 2022-07-07 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JP2024515545A (ja) 2021-04-05 2024-04-10 ブリストル－マイヤーズ スクイブ カンパニー がん治療のためのピリジニル置換オキソイソインドリン化合物
PT4320112T (pt) 2021-04-06 2025-07-07 Bristol Myers Squibb Co Compostos de oxoisoindolina substituídos por piridinilo
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
KR20240037185A (ko) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
US20240226115A1 (en) 2021-05-21 2024-07-11 Arcus Biosciences, Inc. Axl inhibitor compounds
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
CN117940406A (zh) 2021-07-15 2024-04-26 缆图药品公司 Map4k1抑制剂
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
TW202315621A (zh) 2021-08-25 2023-04-16 美商皮克醫療公司 Ｅｉｆ４ｅ抑制劑及其用途
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
EP4416183A4 (en) * 2021-10-12 2025-10-29 Lepu Biopharma Co Ltd SINGLE-DOMAIN ANTI-4-1BB ANTIBODY
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
US20250032618A1 (en) 2021-11-10 2025-01-30 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
JP2025503312A (ja) 2022-02-01 2025-01-30 アルビナス・オペレーションズ・インコーポレイテッド Ｄｇｋ標的化化合物およびその使用
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2025527250A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
JP2025527247A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
KR20250046310A (ko) 2022-08-09 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물
JP2025526681A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
JP2025526727A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
EP4568746B1 (en) 2022-08-11 2026-04-29 F. Hoffmann-La Roche AG Bicyclic tetrahydrothiazepine derivatives
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
TW202430148A (zh) 2022-11-22 2024-08-01 美商皮克醫療公司 ｅＩＦ４Ｅ抑制劑及其用途
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
EP4644417A4 (en) 2022-12-30 2026-02-11 Abclon Inc AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
KR20250019700A (ko) 2023-05-08 2025-02-10 브리스톨-마이어스 스큅 컴퍼니 치환된 페닐 옥사졸론 화합물
WO2024233900A1 (en) 2023-05-10 2024-11-14 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4719607A1 (en) 2023-05-31 2026-04-08 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2024285766A1 (en) 2023-06-07 2026-01-08 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
EP4615455A2 (en) 2023-06-23 2025-09-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2024314878A1 (en) 2023-06-23 2026-01-22 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
TW202519547A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1x4-1BB抗體及其使用方法
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202523350A (zh) 2023-08-10 2025-06-16 美商輝瑞股份有限公司 治療癌症之方法，療法及用途
KR102834908B1 (ko) 2023-09-02 2025-07-16 브리스톨-마이어스 스큅 컴퍼니 치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025059245A1 (en) 2023-09-13 2025-03-20 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
US20260116868A1 (en) 2023-10-06 2026-04-30 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025137370A1 (en) 2023-12-20 2025-06-26 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same
WO2026035787A1 (en) 2024-08-07 2026-02-12 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) macrocyles
WO2026090348A1 (en) 2024-10-24 2026-04-30 Mirati Therapeutics, Inc. The use of son of sevenless (sos) inhibitor compounds such as 7-substituted benzofurans to treat cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP3949712B2 (ja) 1991-12-02 2007-07-25 メディカル リサーチ カウンシル 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
AU5369996A (en) 1995-03-23 1996-10-08 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
KR20030068205A (ko) 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
DE60232895D1 (de) * 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
AU2003259294A1 (en) * 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US20060121030A1 (en) 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2588157A1 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
EP2399935A3 (en) 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
EP1896030A1 (en) 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
WO2007062093A2 (en) 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR100745488B1 (ko) 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
EP2083860A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme PCSK9 ANTAGONISTS
EP2190440A1 (en) 2007-08-13 2010-06-02 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
KR101577843B1 (ko) 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 인간 ｏｘ４０ 수용체에 대한 결합 분자
US20110110944A1 (en) 2008-04-25 2011-05-12 Morphosys Ag Anti-alk1 antibodies and uses thereof
US8745699B2 (en) * 2010-05-14 2014-06-03 Authentify Inc. Flexible quasi out of band authentication architecture
CA2781311C (en) 2009-12-07 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for enhancing anti-tumor antibody therapy
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
EP2699598B1 (en) * 2011-04-19 2019-03-06 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer

Also Published As

Publication number Publication date
TWI520969B (zh) 2016-02-11
AU2011300445B2 (en) 2014-10-09
CN105481983B (zh) 2021-09-03
RU2015110632A (ru) 2015-08-10
US8337850B2 (en) 2012-12-25
US8821867B2 (en) 2014-09-02
TW201812011A (zh) 2018-04-01
US20120237498A1 (en) 2012-09-20
JP2019065038A (ja) 2019-04-25
MX2013002709A (es) 2013-05-22
IL247054A0 (en) 2016-09-29
PL2614082T3 (pl) 2019-02-28
MY162737A (en) 2017-07-14
CA2810359C (en) 2021-06-22
US9468678B2 (en) 2016-10-18
DK2614082T3 (en) 2018-11-26
WO2012032433A1 (en) 2012-03-15
CN103221428A (zh) 2013-07-24
TWI652345B (zh) 2019-03-01
JP2013544756A (ja) 2013-12-19
BR112013005699A2 (pt) 2017-11-21
HUE041958T2 (hu) 2019-06-28
EP2614082A1 (en) 2013-07-17
EP3441404A1 (en) 2019-02-13
IL250386A0 (en) 2017-03-30
KR20130080866A (ko) 2013-07-15
EP2614082B1 (en) 2018-10-03
SI2614082T1 (sl) 2018-12-31
TW201414748A (zh) 2014-04-16
TW201300413A (zh) 2013-01-01
AU2014227437A1 (en) 2014-10-02
NZ700891A (en) 2017-05-26
JP6557648B2 (ja) 2019-08-07
PH12020550156A1 (en) 2024-01-15
CO6690759A2 (es) 2013-06-17
PH12013500395B1 (en) 2020-10-16
AU2011300445A1 (en) 2013-03-14
AR114031A2 (es) 2020-07-15
KR20130079533A (ko) 2013-07-10
TW201625694A (zh) 2016-07-16
CN105481983A (zh) 2016-04-13
SG10201506906VA (en) 2015-10-29
PE20131465A1 (es) 2014-01-04
TWI425005B (zh) 2014-02-01
NZ607710A (en) 2014-11-28
BR112013005699B1 (pt) 2021-08-17
RU2710717C2 (ru) 2020-01-10
CN103221428B (zh) 2016-02-10
MX337040B (es) 2016-02-09
PH12013500395A1 (en) 2013-04-22
AU2018201703A1 (en) 2018-04-05
ES2699648T3 (es) 2019-02-12
AU2014227437B2 (en) 2016-07-28
MX374682B (es) 2025-03-06
NZ729044A (en) 2020-07-31
JP2022046651A (ja) 2022-03-23
AU2016204960A1 (en) 2016-08-04
HK1187627A1 (zh) 2014-04-11
US20130078240A1 (en) 2013-03-28
IL225001A (en) 2016-08-31
US20160369000A1 (en) 2016-12-22
MY177065A (en) 2020-09-03
KR101527297B1 (ko) 2015-06-26
JP2017075164A (ja) 2017-04-20
JP6105470B2 (ja) 2017-03-29
US20140377255A1 (en) 2014-12-25
CA2810359A1 (en) 2012-03-15
IL247054B (en) 2020-06-30
RU2015110632A3 (enExample) 2018-11-30
ZA201502914B (en) 2017-08-30
KR101527300B1 (ko) 2015-06-09
US10640568B2 (en) 2020-05-05
SG10201912092VA (en) 2020-02-27
RU2013110576A (ru) 2014-10-20
US20180194851A1 (en) 2018-07-12
SG188313A1 (en) 2013-04-30
RU2551963C2 (ru) 2015-06-10
PT2614082T (pt) 2018-12-03
HK1222872A1 (zh) 2017-07-14
AR082916A1 (es) 2013-01-16
TWI641621B (zh) 2018-11-21

Similar Documents

Publication Publication Date Title
NZ700891A (en) 4-1bb binding molecules
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MX347164B (es) Anticuerpos anti-il-36r.
PH12013500810B1 (en) Anti-il-23 antibodies
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12014502826A1 (en) Immunoconjugates comprising anti-cd79b antibodies
TN2012000462A1 (en) Anti-cd40 antibodies
SI3309176T1 (sl) Imunoglobulinska protitelesa z enojno variabilno domeno proti OX40L, konstrukti in njihova terapevtska uporaba
PH12012501793B1 (en) Monoclonal antibodies against c-met
NZ626610A (en) Antibodies that bind csf1r
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
NZ611785A (en) Anti-notch1 antibodies
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
EP3019532A4 (en) CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
NZ724395A (en) Anti-pdgf-c antibodies
TN2014000207A1 (en) Anti il-36r antibodies
NZ757754A (en) Antibodies that bind csf1r
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 AUG 2018 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20180412

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2019 BY THOMSON REUTERS

Effective date: 20180721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2020 BY THOMSON REUTERS

Effective date: 20190725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2021 BY THOMSON REUTERS

Effective date: 20200721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2022 BY THOMSON REUTERS

Effective date: 20210701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2023 BY THOMSON REUTERS

Effective date: 20220704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2024 BY THOMSON REUTERS

Effective date: 20230703

LAPS Patent lapsed